NCT01686334 2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT02334735 2022-09-15
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01876212 2019-08-22
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00103116 2017-04-04
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
University of Kentucky
Phase 2 Completed
NCT00913913 2015-12-01
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn